Based on the RAPT Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for RAPT Therapeutics Inc is USD 4.46 over the next 12 months. RAPT Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of RAPT Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, RAPT Therapeutics Inc’s stock price was USD 1.18. RAPT Therapeutics Inc’s stock price has changed by -1.67% over the past week, +0.00% over the past month and -86.47% over the last year.
No recent analyst target price found for RAPT Therapeutics Inc
No recent average analyst rating found for RAPT Therapeutics Inc
Company Overview RAPT Therapeutics Inc
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Read Less
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's ...Read More
Frequently Asked Questions About RAPT Therapeutics Inc (RAPT) Stock
Based on ratings from 7 analysts RAPT Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, 1 sell and 4 hold ratings.
Unfortunately we do not have enough data on RAPT's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for RAPT is USD 4.46 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 2.
RAPT stock's Price/Earning ratio is 0.63.
Our analysis grades RAPT stock's Price / Earning ratio at C. This means that RAPT stock's Price/Earning ratio is above 27% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RAPT may be undervalued for its sector.
The last closing price of RAPT's stock was USD 1.18.
The most recent market capitalization for RAPT is USD 0.15B.
Based on targets from 7 analysts, the average taret price for RAPT is projected at USD 4.46 over the next 12 months.
This means that RAPT's stock price may go up by +277.86% over the next 12 months.
We can't find any ETFs which contains RAPT Therapeutics Inc's stock.
As per our most recent records RAPT Therapeutics Inc has 70 Employees.
RAPT Therapeutics Inc's registered address is 561 Eccles Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from RAPT Therapeutics Inc's website at https://www.rapt.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About RAPT Therapeutics Inc (RAPT) Stock
Based on ratings from 7 analysts RAPT Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 3 buy, 1 sell and 4 hold ratings.
Unfortunately we do not have enough data on RAPT's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for RAPT is USD 4.46 over the next 12 months. The maximum analyst target price is USD 10 while the minimum anlayst target price is USD 2.
RAPT stock's Price/Earning ratio is 0.63.
Our analysis grades RAPT stock's Price / Earning ratio at C. This means that RAPT stock's Price/Earning ratio is above 27% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this RAPT may be undervalued for its sector.
The last closing price of RAPT's stock was USD 1.18.
The most recent market capitalization for RAPT is USD 0.15B.
Based on targets from 7 analysts, the average taret price for RAPT is projected at USD 4.46 over the next 12 months.
This means that RAPT's stock price may go up by +277.86% over the next 12 months.
We can't find any ETFs which contains RAPT Therapeutics Inc's stock.
As per our most recent records RAPT Therapeutics Inc has 70 Employees.
RAPT Therapeutics Inc's registered address is 561 Eccles Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from RAPT Therapeutics Inc's website at https://www.rapt.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RAPT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
